PTC Therapeutics, Inc. (PTCT)

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential

PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal

PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'

PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript

PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PTC Therapeutics, Inc. $PTCT Shares Purchased by Fifth Third Bancorp

Hamilton Lane Board Elects Michael Schmertzler as New Independent Director

PTC Therapeutics, Inc. $PTCT Shares Purchased by Bessemer Group Inc.

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026

What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million

Reasons Why Investors Should Consider Betting on PTC Stock Now

Stocks Look Shaky, But This Sector is Booming (Biotech)

PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know

CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data